Labcorp Raises Annual Forecasts Following Quarterly Earnings Beat

Key Facts

Labcorp has upwardly revised its full-year profit and revenue guidance after delivering quarterly financial results that surpassed market expectations. For the first quarter of CY2026, the company reported a 5.8% year-on-year sales increase to $3.54 billion, exceeding analyst estimates. Following the positive report, Labcorp's stock (LH) surged 5.5% to trade at $271.20. This robust performance is primarily attributed to the resilient and steady demand for its core diagnostic testing services. The positive momentum in the diagnostics segment has provided management with the confidence to raise its annual outlook, signaling strong operational health. Investors remain focused on the company's ability to maintain this growth trajectory within the healthcare sector.

Version History